Edition:
India

People: Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

28.38CAD
23 Aug 2019
Change (% chg)

$-1.02 (-3.47%)
Prev Close
$29.40
Open
$29.08
Day's High
$29.45
Day's Low
$28.25
Volume
675,367
Avg. Vol
699,875
52-wk High
$36.52
52-wk Low
$23.60

Herendeen, Paul 

Mr. Paul S. Herendeen is Chief Financial Officer, Executive Vice President of the company. He has been our Executive Vice President and Chief Financial Officer since August 2016. Prior to joining Bausch Health, he served as Executive Vice President and CFO of Zoetis Inc. for two years. From 2005 to 2013 and from 1998 to 2001, Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe Pharmaceuticals, a privately held healthcare company, where he served as CFO from 2001 until 2005. Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and as a senior auditor with Arthur Andersen & Company. Mr. Herendeen earned a Master of Business Administration from the University of Virginia’s Darden School of Business and holds a bachelor’s degree in Business Administration from Boston College.

Basic Compensation

Total Annual Compensation, USD 1,000,000
Restricted Stock Award, USD 2,310,570
Long-Term Incentive Plans, USD --
All Other, USD 3,090,240
Fiscal Year Total, USD 6,400,810

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Papa

14,741,000

Paul Herendeen

6,400,810

Thomas Appio

4,386,600

Joseph Gordon

1,962,200

William Humphries

8,434,210

Mark McKenna

--
As Of  31 Dec 2018